Merck plans to discuss the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season, according to a release.
The trial examined the safety and efficacy of a single dose of the treatment, clesrovimab, in healthy preterm and full-term infants entering their first RSV season.
Results were consistent through both the five-month and six-month time points in the trial, Merck said.
Merck's clesrovimab could potentially compete against a similar treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide last RSV season due to unprecedented demand.
But Merck's treatment can be administered to infants regardless of their weight, which the company said may offer convenience in terms of dosing.
Persons:
Merck, Clesrovimab, Dr, Octavio Ramilo, Ramilo, Merck's
Organizations:
Merck, New York Stock Exchange, Infectious, Research, Sanofi, AstraZeneca, Pfizer, GSK
Locations:
Los Angeles, St